Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Parkinson's Disease

  Free Subscription


19.02.2018

1 Exp Neurol
1 J Neural Transm (Vienna)
1 J Neurol Neurosurg Psychiatry
11 Mov Disord
1 Nature
1 Nervenarzt
2 Neurol Clin Pract
3 Neurology
1 PLoS One
1 Rev Neurol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Exp Neurol

  1. SUN X, Aime P, Dai D, Ramalingam N, et al
    Guanabenz promotes neuronal survival via enhancement of ATF4 and parkin expression in models of Parkinson disease.
    Exp Neurol. 2018 Feb 9. pii: S0014-4886(18)30022.
    PubMed     Text format     Abstract available


    J Neural Transm (Vienna)

  2. VESELY B, Dufek M, Thon V, Brozman M, et al
    Interleukin 6 and complement serum level study in Parkinson's disease.
    J Neural Transm (Vienna). 2018 Feb 12. pii: 10.1007/s00702-018-1857.
    PubMed     Text format     Abstract available


    J Neurol Neurosurg Psychiatry

  3. ABBES M, Lhommee E, Thobois S, Klinger H, et al
    Subthalamic stimulation and neuropsychiatric symptoms in Parkinson's disease: results from a long-term follow-up cohort study.
    J Neurol Neurosurg Psychiatry. 2018 Feb 7. pii: jnnp-2017-316373.
    PubMed     Text format     Abstract available


    Mov Disord

  4. NAROS G, Grimm F, Weiss D, Gharabaghi A, et al
    Directional communication during movement execution interferes with tremor in Parkinson's disease.
    Mov Disord. 2018;33:251-261.
    PubMed     Text format     Abstract available

  5. MAHLKNECHT P, Gasperi A, Djamshidian A, Kiechl S, et al
    Performance of the Movement Disorders Society criteria for prodromal Parkinson's disease: A population-based 10-year study.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27281.
    PubMed     Text format     Abstract available

  6. MULAK A
    A controversy on the role of short-chain fatty acids in the pathogenesis of Parkinson's disease.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27304.
    PubMed     Text format    

  7. ABBASI N, Mohajer B, Abbasi S, Hasanabadi P, et al
    Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson's disease.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27284.
    PubMed     Text format     Abstract available

  8. PALMA JA
    Autonomic dysfunction in Parkinson's disease and other synucleinopathies: Introduction to the series.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27347.
    PubMed     Text format    

  9. DAGAN M, Herman T, Harrison R, Zhou J, et al
    Multitarget transcranial direct current stimulation for freezing of gait in Parkinson's disease.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27300.
    PubMed     Text format     Abstract available

  10. BOUCA-MACHADO R, Lennaerts-Kats H, Bloem B, Ferreira JJ, et al
    Why palliative care applies to Parkinson's disease.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27309.
    PubMed     Text format    

  11. FAZIO P, Svenningsson P, Cselenyi Z, Halldin C, et al
    Nigrostriatal dopamine transporter availability in early Parkinson's disease.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27316.
    PubMed     Text format     Abstract available

  12. SAMOTUS O, Parrent A, Jog M
    Spinal cord stimulation therapy for gait dysfunction in advanced Parkinson's disease patients.
    Mov Disord. 2018 Feb 14. doi: 10.1002/mds.27299.
    PubMed     Text format     Abstract available

  13. PARK JS, Koentjoro B, Klein C, Sue CM, et al
    Single heterozygous ATP13A2 mutations cause cellular dysfunction associated with Parkinson's disease.
    Mov Disord. 2018 Feb 14. doi: 10.1002/mds.27327.
    PubMed     Text format    

  14. WYMAN-CHICK KA, Martin PK, Weintraub D, Sperling SA, et al
    Selection of normative group affects rates of mild cognitive impairment in Parkinson's disease.
    Mov Disord. 2018 Feb 14. doi: 10.1002/mds.27335.
    PubMed     Text format     Abstract available


    Nature

  15. CHECK HAYDEN E
    The rise and fall and rise again of 23andMe.
    Nature. 2017;550:174-177.
    PubMed     Text format    


    Nervenarzt

  16. GOVERT F, Becktepe J, Deuschl G
    [The new tremor classification of the International Parkinson and Movement Disorder Society : Update on frequent tremors].
    Nervenarzt. 2018 Feb 13. pii: 10.1007/s00115-018-0489.
    PubMed     Text format     Abstract available


    Neurol Clin Pract

  17. MITTAL SO, Hassan A, Sanchez J, Robertson C, et al
    Powassan virus postencephalitic parkinsonism.
    Neurol Clin Pract. 2017;7:527-530.
    PubMed     Text format    

  18. RENGA V, Hickey WF, Bernat JL
    Spontaneous periodic hypothermia in Parkinson disease with hypothalamic involvement.
    Neurol Clin Pract. 2017;7:538-540.
    PubMed     Text format    


    Neurology

  19. WEISS D, Massano J
    Approaching adaptive control in neurostimulation for Parkinson disease: Autopilot on.
    Neurology. 2018 Feb 14. pii: WNL.0000000000005111.
    PubMed     Text format    

  20. ARLOTTI M, Marceglia S, Foffani G, Volkmann J, et al
    Eight-hours adaptive deep brain stimulation in patients with Parkinson disease.
    Neurology. 2018 Feb 14. pii: WNL.0000000000005121.
    PubMed     Text format     Abstract available

  21. HONMA M, Masaoka Y, Kuroda T, Futamura A, et al
    Impairment of cross-modality of vision and olfaction in Parkinson disease.
    Neurology. 2018 Feb 7. pii: WNL.0000000000005110.
    PubMed     Text format     Abstract available


    PLoS One

  22. PUSHPANATHAN ME, Loftus AM, Gasson N, Thomas MG, et al
    Beyond factor analysis: Multidimensionality and the Parkinson's Disease Sleep Scale-Revised.
    PLoS One. 2018;13:e0192394.
    PubMed     Text format     Abstract available


    Rev Neurol

  23. BENITO-LEON J
    [Epidemiology of Parkinson's disease in Spain and its contextualisation in the world].
    Rev Neurol. 2018;66:125-134.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: